Justin Leong
Known title: Chief Product OfficerCIK: 0001825782
Associated companies
Transaction History
| RMD | ▲ Buy | Grant | 6,461 | $0 | 8/14/2026 | View on chart |
| RMD | ▲ Buy | Grant | 1,848 | $0 | 11/20/2025 | View on chart |
| RMD | ▲ Buy | Grant | 5,462 | $0 | 8/15/2025 | View on chart |
| RMD | ▼ Sell | Open Market | 6,160 | $1.5M | 11/22/2024 | View on chart |
| RMD | ▲ Buy | Grant | 8,259 | $0 | 8/15/2024 | View on chart |
| RMD | ▲ Buy | Grant | 878 | $0 | 8/15/2024 | View on chart |
| RMD | ▼ Sell | Open Market | 48,000 | $10.4M | 8/5/2024 | View on chart |
| RMD | ▲ Buy | Grant | 6,924 | $0 | 11/23/2022 | View on chart |
| RMD | ▲ Buy | Option Exercise | 15,000 | $866K | 11/22/2022 | View on chart |
| RMD | ▼ Sell | Open Market | 3,777 | $867K | 11/22/2022 | View on chart |
| RMD | ▼ Sell | Tax Withholding | 1,339 | $341K | 11/24/2021 | View on chart |
| RMD | ▲ Buy | Grant | 638 | $0 | 11/18/2021 | View on chart |
| RMD | ▲ Buy | Grant | 9,162 | $2.3M | 11/16/2021 | View on chart |
| RMD | ▲ Buy | Grant | 2,631 | $0 | 8/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ResMed Q4 2026 Earnings Call Transcript Released
ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.
ResMed Q4 2026 Earnings Call Transcript Released. ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.